Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 10:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Triglycerides High Clear all
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides

NCT01262638
View directory record Official record
Conditions
Dyslipidemia
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
11
States / cities
Chandler, Arizona • Greenbrae, California • Santa Rosa, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Almonds on Cardiovascular Risk Factors

NCT01101230
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Almonds
Other
Lead sponsor
Penn State University
Other
Eligibility
30 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 3 Interventional Results available

Epanova® for Lowering Very High Triglycerides II (EVOLVE II)

NCT02009865
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Epanova, Olive Oil
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Los Angeles, California • St. Petersburg, Florida • Addison, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 4 Interventional Results available

Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy

NCT02926027
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Vascepa, placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
30 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Torrance, California • Murray, Utah
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects

NCT00903409
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Simvastatin + Lovaza® (omega-3-acid ethyl esters)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
40
States / cities
Mobile, Alabama • Encinitas, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2017 · Synced Jun 10, 2026, 10:06 AM EDT
Recruiting Phase 2 Interventional

A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

NCT07199309
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
MAR001, Placebo
Drug
Lead sponsor
Marea Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Habitual Diet and Avocado Trial

NCT03528031
View directory record Official record
Conditions
Intra-abdominal Fat, Metabolic Syndrome, High Cholesterol, Triglycerides High, Diet Habit, High Blood Sugar, Liver Fat, Dietary Modification, HDL Cholesterol, Low Serum, Cardiovascular Diseases, High Density Lipoprotein Deficiency, Low-density-lipoprotein-type, Cardiovascular Risk Factor, Diabetes
Interventions
Intervention Daily Avocado
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
25 Years and older
Enrollment
1,008 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
4
States / cities
Loma Linda, California • Los Angeles, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.

NCT00186537
View directory record Official record
Conditions
Insulin Resistance, Hypertriglyceridemia
Interventions
Rosiglitazone, Fenofibrate, Weight Loss
Drug · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jun 10, 2026, 10:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pharmacokinetics and Pharmacodynamics of Fructose

NCT00661947
View directory record Official record
Conditions
Healthy
Interventions
Dr Pepper sweetened with sucrose or high fructose corn syrup
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol ("Bad Cholesterol") and Triglycerides

NCT00812955
View directory record Official record
Conditions
Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions
ABT-143, simvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
129
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 4 Interventional Results available

The Impact of Omega Three Fatty Acids on Vascular Function in HIV

NCT01041521
View directory record Official record
Conditions
High Triglyceride Level, HIV Infection
Interventions
Lovaza
Drug
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients

NCT01811472
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
LCQ908, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
11
States / cities
Mobile, Alabama • San Diego, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Jun 10, 2026, 10:06 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Bioavailability of EPA and DHA From Two Dietary Supplements

NCT01908374
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
DHA-rich fish oil versus Phospholipid-rich fish oil
Dietary Supplement
Lead sponsor
Arctic Nutrition AS
Industry
Eligibility
18 Years to 59 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Not applicable Interventional

Effect of a Grape Seed Extract (GSE) on Insulin Resistance

NCT01889368
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Grape Seed Extract, Placebo
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
20 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Mather, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Not applicable Interventional Results available

Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides

NCT00504309
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
4/day of 4g P-OM3 capsules, 4/day of 1g P-OM3 capsules, Corn Oil Placebo, 4 capsules/day for 8 weeks
Drug
Lead sponsor
Penn State University
Other
Eligibility
21 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 2 Interventional

Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia

NCT05889156
View directory record Official record
Conditions
High Triglycerides
Interventions
NST-1024, Placebo
Drug · Other
Lead sponsor
NorthSea Therapeutics B.V.
Industry
Eligibility
18 Years to 79 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
31
States / cities
Birmingham, Alabama • Daphne, Alabama • Tempe, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Jun 10, 2026, 10:06 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Therapeutic Omegas for Triglyceride Suppression

NCT04349475
View directory record Official record
Conditions
Pregnancy
Interventions
Intervention Omega 3 Supplementation, Placebo Soybean Oil
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
0 Years to 39 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 10, 2026, 10:06 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides

NCT00672633
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Lovaza, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
10 Years to 19 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2013 · Synced Jun 10, 2026, 10:06 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

High Fat Meal and Postprandial TG Levels With and Without Exercise Intervention

NCT05291767
View directory record Official record
Conditions
Ketogenic Diet, Exercise
Interventions
Diet, Exercise
Other · Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 4 Interventional Results available

Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia

NCT00833976
View directory record Official record
Conditions
High Triglycerides, Hypercholesterolemia, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Lovaza
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study

NCT00400231
View directory record Official record
Conditions
Metabolic Syndrome x
Interventions
Study drugs: Metformin and fenofibrate, Study Drug: Metformin, Study Drug: fenofibrate, Metformin and Fenofibrate placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 2 Interventional Results available

Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

NCT03371355
View directory record Official record
Conditions
NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic
Interventions
Placebo, ISIS 703802 40 mg, ISIS 703802 80 mg, ISIS 703802 20 mg
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Chandler, Arizona • Fountain Hills, Arizona • Glendale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 4 Interventional Results available

A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™

NCT00891293
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
32
States / cities
Spring Valley, California • Washington D.C., District of Columbia • Coral Gables, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Change of Fructose to Fat in South Asians

NCT01562782
View directory record Official record
Conditions
Elevated Triglycerides, Diabetes, Cardiovascular Disease, Dyslipidemia
Interventions
Fructose + Glucose Beverage
Other
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years to 35 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Jun 10, 2026, 10:06 AM EDT